Gauchers News Contents
Prof Timothy Cox used the location of the EWGGD meeting in the Czech Republic to highlight his opening lecture (summarised below) on European scientific thought that had developed in Europe since the years of the Enlightenment in the 17th - 18th Century when the basic conviction was that through reason mankind could find knowledge and happiness.
Born in Moravia (now the Czech Republic) in 1592, Jan Comenius was one of the founding fathers of education and science in central and many parts of Europe. As a result of his influence, the spirit of enquiry in education was fostered and this tradition enriched the early life and genius of the monk Gregor Mendel who discovered modern genetics. He later became Abbott of the Augustinian monastery in Brno which lies about 120 miles east of Prague.
Mendel observed the inheritance of different characteristics in garden peas and other plants and carried out ambitious experiments over a period of eight years. He produced one brilliant paper in 1865-6 whose content was tragically ignored for almost 50 years but his discoveries provided evidence of the hereditary material (now known to be DNA) on which evolutionary selection operates.
Mendel's personal copies of Charles Darwin's Origin of Species have been discovered; they contain his annotations of Darwin's text and he must have secretly realised the great significance of his own work. Element of a Happy Guess Science is knowledge which has to be logically connected, predictive and testable but there is always an element of a happy guess at the start. Gauchers disease is an example of how the application of science has led to therapeutic discovery.
Although the condition is rare, there are sufficient numbers of patients to render pharmaceutical research worthwhile from the commercial aspect.
Participation of Patients
Many medical investigators have documented the disease's clinical, pathological, biochemical and genetic features and this has provided the foundation for drug design and for clear documentation of the effects of therapy.
All this clinical research has been based on the study of patients directly. Were it not for the thorough characterisation of Gauchers disease and the willing participation of patients in clinical trials, the salutary effects of therapy would not have been so clearly shown.
Orphan drug legislation, introduced in recognition of unmet needs in society, was an additional powerful incentive to therapeutic development.
Little Known Aspects of the Disease
Prof Cox devoted much of his lecture to little known aspects of Gauchers disease and the mechanism of action of different therapies real and potential.
He explained that effective treatment depends on a complete understanding of the disease process itself. It is still not possible to make the mechanistic connection between the presence of a few grams of storage material and the complex syndrome termed Gauchers disease and that despite its effectiveness, neither enzyme replace-ment nor any other therapy actually cures the condition.
Refinements in existing medicines or the introduction of new strategies, including gene therapy, are justified for the advancement of Gauchers disease and related lysosomal diseases and this all required more investment in fundamental research.
There are other puzzles too: it is recognized that unknown environ-mental factors may operate to explain why, in the case of two identical twin sisters having the same glucocere-brosidase gene mutations and with the same complement of DNA, only one developed symptoms and needed a splenectomy whilst the other twin remained healthy.
The nature of the gene-environment interactions that induce or exacerbate clinical disease perhaps remains even more of a mystery. A completely novel experimental approach is going to be needed to understand these interactions in human medicine.
Just as Medicine depends on continuing scientific development and experimental work, Science too owes a huge debt to Medicine. The European Working Group on Gaucher Disease clearly had plenty of research opportunities in to the disease.
Gauchers News Contents
Source: Gauchers News October 2002.
© Copyright Gauchers Association 2002